One intronic variant in JAG1 (rs6040062) was significantly associated with shorter overall survival (HRG > C: 1.36, 95% CI: 1.15–1.61, p-value: 0.0003, Table 2a) and recurrence-free survival (HRG > C: 1.31, 95% CI: 1.09–1.57, p-value: 0.004, Table S4) of colorectal cancer patients. Here, JAG1 is linked to colorectal cancer.